These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32153224)

  • 1. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 Apr; 13(4):331-349. PubMed ID: 32153224
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging antibodies for the treatment of multiple myeloma.
    Zagouri F; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):225-37. PubMed ID: 27195659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
    De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 May; 13(5):501-517. PubMed ID: 32290723
    [No Abstract]   [Full Text] [Related]  

  • 7. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies in the Treatment of Multiple Myeloma.
    van de Donk NWCJ; Zweegman S
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):337-360. PubMed ID: 38151402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates in the management of relapsed/refractory multiple myeloma.
    Hanna KS; Larson S; Nguyen J; Tu S; Boudreau J; Rose S
    J Oncol Pharm Pract; 2021 Sep; 27(6):1477-1490. PubMed ID: 34162244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment.
    Morè S; Petrucci MT; Corvatta L; Fazio F; Offidani M; Olivieri A
    Pharmaceuticals (Basel); 2020 Nov; 13(12):. PubMed ID: 33260960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies in Myeloma: Optimizing Targeted Therapy.
    Hartley-Brown M; Chitty D; Thakur R
    Cancer J; 2021 May-Jun 01; 27(3):222-230. PubMed ID: 34549911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.